ArticleDiagnostic pathology2014
Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Granulosa cell tumors and menopausal hormone therapy: A narrative review.Gynecologic oncology reports · 2026Review
- Estrogen receptor α expression in tumor-infiltrating lymphocytes from patients with endometrial cancer.Oncology letters · 2026Article
- Progesterone receptor isoform modulation via enhancer activation regulates progesterone signaling in endometrial stromal cells.F&S science · 2025Article
- Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer.Fundamental research · 2025Review
- Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.International journal of molecular sciences · 2024Review
- EPPK1 as a Prognostic Biomarker in Type I Endometrial Cancer and Its Correlation with Immune Infiltration.International journal of general medicine · 2024Article
- Roles of estrogen receptor α in endometrial carcinoma (Review).Oncology letters · 2023Review
- The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer.International journal of molecular sciences · 2023Article
- Cancer-associated fibroblasts in gynecological malignancies: are they really allies of the enemy?Frontiers in oncology · 2023Review
- Article
- Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer.Clinical Medicine Insights. Oncology · 2022Article
- miR-497-5p Decreased Expression Associated with High-Risk Endometrial Cancer.International journal of molecular sciences · 2020Article
- Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.Journal of Cancer · 2020Article
- Prognostic molecular biomarkers in endometrial cancer: A review.Journal of cancer research & therapy · 2019Article
- Expression of ELF5 in endometrial carcinoma tissues and its clinical significance.Oncology letters · 2018Article
- Long-term effects of repeated superovulation on the uterus and mammary gland in rhesus monkeys.Journal of assisted reproduction and genetics · 2017Article
- Review
- Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?Oncotarget · 2017Article
- Evaluation of the Pathogenesis of Tumor Development from Endometriosis by Estrogen Receptor, P53 and Bcl-2 Immunohistochemical StainingAsian Pacific journal of cancer prevention : APJCP · 2016Article
- Regulation of epithelial-mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background70-80% of sporadic endometrial carcinomas are defined as endometrioid carcinoma (EC). Early-stage, well differentiated endometrial carcinomas usually retain expression of estrogen and progesterone receptors (ER and PR, respectively), as advanced stage, poorly differentiated tumors often lack one or both of these receptors. Well-described EC prognosis includes tumor characteristics, such as depth of myometrial invasion. Therefore, in the current study, we evaluated the expression profile of ER and PR isoforms, including ER-α, PR-A and PR-B, in correlation to EC tumor histological depth.
methodsUsing immunohistochemistry and image analysis software, the expression of ER-α, PR-A, PR-B and Ki67 was assessed in endometrial stroma and epithelial glands of superficial, deep and extra-tumoral sections of 15 paraffin embedded EC specimens, and compared to 5 biopsies of non-malignant endometrium.
resultsExpression of PR-A and ER-α was found to be lower in EC compared to nonmalignant tissue, as the stromal expression was dramatically reduced compared to epithelial cells. Expression ratios of both receptors were significantly high in superficial and deep portions of EC; in non-tumoral portion of EC were close to the ratios of nonmalignant endometrium. PR-B expression was low in epithelial glands of EC superficial and deep portions, and high in the extra-tumoral region. Elevated PR-B expression was found in stroma of EC, as well.
conclusionsThe ratio of ER-α and PR-A expression in the epithelial glands and the stroma of EC biopsies may serve as an additional parameter in the histological evaluation of EC tumor. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1155060506119016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.